Verition Fund Management
WHWK

Verition Fund Management’s Whitehawk Therapeutics WHWK Stock Holding History

Verition Fund Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-82,361
Closed -$120K – 3563
2024
Q2 		$120K Buy
82,361
+50,166
+156% +$93K ﹤0.01% 2707
2024
Q1 		$75.3K Buy
+32,195
New +$62.1K ﹤0.01% 2608
2023
Q2 		– Sell
-17,879
Closed -$129K – 2608
2023
Q1 		$129K Buy
+17,879
New +$191K ﹤0.01% 1876

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's WHWK Position: Q3 2024 in Review

Verition Fund Management sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 82,361 shares — an estimated $120K sold.

Verition Fund Management first reported a position in WHWK in Q1 2023 and held it in 3 quarters. The position peaked at $129K in Q1 2023. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • Verition Fund Management reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Verition Fund Management sold 82,361 Whitehawk Therapeutics shares in Q3 2024, an estimated $120K.
  • Verition Fund Management first reported a position in Whitehawk Therapeutics in Q1 2023 and held it in 3 quarters.
  • Verition Fund Management's Whitehawk Therapeutics position peaked at $129K in Q1 2023.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on Verition Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.